CFR
Cullen/Frost BankersCAI scenario view
RankAlpha Sentiment CodexPost-earnings T+3The current persistence contract does not provide an exact AI reference price. RankAlpha therefore does not calculate scenario return from the live quote. How scenarios are presented
AI sentiment snapshot
AI commentary
Primary-company evidence is fundamentally constructive but mixed: earnings, loans, deposits, NIM, fees, capital, dividends, and buybacks were positive, while credit metrics and competition require monitoring. The stock closed at $163.49 on July 30, down 2.06%, then recovered to the August 3 RankAlpha anchor of $168.94. The reviewed analyst page showed only pre-print actions through July 15 and no post-print revision, so analyst confirmation remains unavailable. Social coverage was not supplied. ([Benzinga analyst ratings](https://www.benzinga.com/quote/CFR/analyst-ratings))
Evidence flagged
later post-earnings follow-up lacks concrete company-source and analyst/market reaction evidence
AI events
CFR declared a $1.03 third-quarter common dividend payable September 15, 2026 and repurchased $90 million of stock during Q2, with $140 million remaining under its authorization. [#SEC-8K-2026-07-30]
CFR reported Q2 EPS of $2.70, up 13% year over year; average loans rose 7.4%, deposits 2.1%, net interest income 4.3%, net interest margin reached 3.75%, and non-interest income rose 9.4%. Capital ratios remained above well-capitalized levels. Benzinga recorded a July 30 close of $163.49, down 2.06%; the RankAlpha August 3 anchor was $168.94, indicating partial recovery. [#SEC-8K-2026-07-30] ([Benzinga analyst ratings](https://www.benzinga.com/quote/CFR/analyst-ratings))
The official release showed non-accrual loans rising to $112.7 million from $72.4 million sequentially, while credit-loss expense and net charge-offs increased sequentially. Stored earnings context also reports intensified competition in Texas lending and an isolated multifamily CRE nonperformer. [#SEC-8K-2026-07-30] [#PR-EARNINGS-2026-07-31]
Recommendation
No formal recommendation provided.

